STAROGARD GDANSKI, Poland, June 2, 2016 /PRNewswire/ --
On 1 June 2016, Markus Sieger was appointed President of the Management Board and CEO of Polpharma SA, succeeding Maurice Chagnaud. The main responsibility of the new CEO is to accelerate Polpharma Group's growth to become a leader in the CEE, CIS and Central Asia regions and drive strategic development in the biotechnology sector.
(Logo: http://photos.prnewswire.com/prnh/20160602/374706LOGO )
(Photo: http://photos.prnewswire.com/prnh/20160602/374707 )
Markus Sieger holds a degree in Economics from the University of Applied Sciences for Business and Administration in Zurich. Since the mid-nineties, he has built up a strong track record in successfully managing complex and strategic transactions in and outside of Poland for pharmaceutical and FMCG companies. Since 2013, he has been involved in supervision and management of Polpharma Group as a member of the Supervisory Board of Polpharma. Being a member of several supervisory boards, he has a considerable experience in supervising activities of both private and public companies. He supported the strategic development of two Polish media companies, TVN and Onet.
"I have been co-operating with Markus Sieger very closely for more than 20 years. We share a common vision on how to develop and manage Polpharma to become a regional leader in CEE, CIS and Central Asia and an important player in the development, production and commercialization of biologic drugs. I am convinced that Markus Sieger will successfully lead the company to achieve those targets by effectively exploiting all business opportunities and new market trends", said Jerzy Starak, owner and Chairman of the Supervisory Board of Polpharma SA.
"I am very happy about the decision of the Supervisory Board. The company has an excellent position in its markets and a clear vision on how to develop in the future. I am looking forward, jointly with my strong team, to achieving the set targets", said Markus Sieger.
Polpharma is the leading Polish generics producer, operating across Europe, the Caucasus and Central AsiaIt is among the top 20 global generic companies with annual sales of nearly $1 billion. It is also one of the leading European API producers, delivering products worldwide. In order to provide patients with more affordable access to modern therapies, Polpharma has decided to invest in biosimilars. It has created a state-of-the-art R&D and production center and established strategic partnerships to expand its capabilities in biosimilars on a global scale.
CONTACT: Magdalena Rzeszotalska, email@example.com,+48-607-696-473